<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>23507335</identifier>
<setSpec>1578-6749</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Muñoz, M</dc:author>
<dc:author>López-Briz, E</dc:author>
<dc:author>Torrabadella, P</dc:author>
<dc:author>Fernández-Mondéjar, E</dc:author>
<dc:author>Asuero, M</dc:author>
<dc:author>Ruiz, J C</dc:author>
<dc:author>Sánchez, C</dc:author>
<dc:author>Bisbe, E</dc:author>
<dc:author>Montoro-Ronsano, B</dc:author>
<dc:author>Fernández-Hinojosa, E</dc:author>
<dc:author>Leal-Noval, S R</dc:author>
<dc:author>Ferrándiz, C</dc:author>
<dc:author>Llau, J V</dc:author>
<dc:author>Izuel, M</dc:author>
<dc:author>Arellano, V</dc:author>
<dc:author>Contreras, E</dc:author>
<dc:author>Bautista-Paloma, F J</dc:author>
<dc:author>Castillo-Muñoz, A</dc:author>
<dc:author>Romero-Garrido, J A</dc:author>
<dc:author>Gómez-Luque, A</dc:author>
<dc:author>Jiménez-Yuste, V</dc:author>
<dc:author>Quintana, M</dc:author>
<dc:author>Fernández, J A</dc:author>
<dc:author>Candela, A</dc:author>
<dc:author>Páramo, J A</dc:author>
<dc:author>Gomar, C</dc:author>
<dc:author>Basora, M</dc:author>
<dc:author>Puppo, A</dc:author>
<dc:author>García de Lorenzo, A</dc:author>
<dc:author>Fernández, C</dc:author>
<dc:author>Colomina, M J</dc:author>
<dc:author>López-Fernández, M L</dc:author>
<dc:author>Moral, V</dc:author>
<dc:author>García-Erce, J A</dc:author>
<dc:author>Bóveda, J L</dc:author>
<dc:author>Paniagua, C</dc:author>
<dc:author>Martín-Conde, J A</dc:author>
<dc:author>Salinas-Argente, R</dc:author>
<dc:description xml:lang="en">Since allogeneic blood transfusion (ABT) is not harmless, multiple alternatives to ABT (AABT) have emerged, though there is great variability in their indications and appropriate use. This variability results from the interaction of a number of factors, including the specialty of the physician, knowledge and preferences, the degree of anemia, transfusion policy, and AABT availability. Since AABTs are not harmless and may not meet cost-effectiveness criteria, such variability is unacceptable. The Spanish Societies of Anesthesiology (SEDAR), Hematology and Hemotherapy (SEHH), Hospital Pharmacy (SEFH), Critical Care Medicine (SEMICYUC), Thrombosis and Hemostasis (SETH) and Blood Transfusion (SETS) have developed a Consensus Document for the proper use of AABTs. A panel of experts convened by these 6 Societies have conducted a systematic review of the medical literature and have developed the 2013 Seville Consensus Document on Alternatives to Allogeneic Blood Transfusion, which only considers those AABT aimed at decreasing the transfusion of packed red cells. AABTs are defined as any pharmacological or non-pharmacological measure aimed at decreasing the transfusion of red blood cell concentrates, while preserving patient safety. For each AABT, the main question formulated, positively or negatively, is: « Does this particular AABT reduce the transfusion rate or not?» All the recommendations on the use of AABTs were formulated according to the Grades of Recommendation Assessment, Development and Evaluation (GRADE) methodology.</dc:description>
<dc:type>Consensus Development Conference</dc:type>
<dc:language>es</dc:language>
<dc:date>2013 May </dc:date>
<dc:title xml:lang="es">2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla.</dc:title>
<dc:title xml:lang="en">[The 2013 Seville Consensus Document on alternatives to allogenic blood transfusion. An update on the Seville Document].</dc:title>
<dc:publisher>Medicina intensiva</dc:publisher>
</metadata>
</record>
</pubmed-document>
